into which MSA brain extracts were intracerebrally injected. By reviewing the findings obtained from these model systems, we will discuss what we have learned about the disease and describe the strengths and limitations of the models, thereby ultimately providing direction for ...
Can multiple system atrophy clinically be misdiagnosed as corticobasal syndrome in the early stagesdoi:10.18502/CJN.V20I2.6748Saeedi, YasamanEmamikhah, MaziarShoeibi, AliRohani, MohammadTehran University of Medical SciencesCurrent Journal of Neurology...
Multiple System Atrophy (MSA) is a rare, fatal neurodegenerative disorder. Its etiology and exact pathogenesis still remain poorly understood and currently no disease-modifying therapy is available to halt or slow down this detrimental neurodegenerative process. Hallmarks of the disease are α-synuclein ...
Multiple System Atrophy (MSA) and Parkinson's diseases (PD) are elite members of the α-synucleinopathy organization. Aberrant accumulations of the protein α-synuclein characterize them. A plethora of evidence indicates the involvement of these rogue inclusions in a cascade of events that disturb ...
Moreover, [156] reports articulatory differences in progressive supranuclear palsy, multiple system atrophy, and PD, especially when analyzing VOT. Moreover, there are other challenges that machine learning approaches have to overcome to derive into more reliable and causally robust diagnosis systems [...
 There is currently no cure for Multiple System Atrophy; The lack of awareness about Multiple System Atrophy has hindered research and the ability of researchers to obtain funding for their work;  Public support and greater awareness of the need for research funding can aid in the discove...
Introduction The clinical differentiation of Parkinson's disease (PD) from multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) may be challenging, especially in their early stages. The aim of this study was to evaluate the utility of apparent diffusion coefficient (ADC) measurement...
Acute MS (malignant MS; n = 12) patients exhibited a rapidly progressing disease course, leading to significant disability in multiple neurological systems and often to death.37 Classical or chronic MS (n = 10) patients exhibited relapsing-remitting, secondary progressive, primary progressive disease...
similar to the glial cytoplasmic inclusions of multiple system atrophy (MSA). Both inclusion types were ubiquitin and p62 positive and were labelled with phosphorylation-dependent anti-α-synuclein antibodies In addition, TDP-43 immunoreactive inclusions were observed in limbic regions and in the ...
CNS atrophy, which involves both gray and white matter, is a progressive phenomenon that worsens with increasing disease duration and progresses at a rate of 0.6% to 1.2% of brain loss per year. Quantitative measures of whole-brain atrophy, acquired by automated or semi-automated methods, ...